The effects of nano-curcumin on obstructive pulmonary disease patients

Phase 3

• Conditions: chronic obstructive pulmonary disease.; Chronic obstructive pulmonary disease, unspecified; J44.9

• Registration Number: IRCT20191222045853N1
• Lead Sponsor: Oroumia University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 November 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Adult age range (18-65 years).
Smokers who have been smoking for at least 10 years.
Confirmation of chronic obstructive pulmonary disease according to GOLD criteria.
The patient has stages 3 and 4 of chronic pulmonary obstruction.

Exclusion Criteria

Patient with gallstones
Infectious diseases
Gastrointestinal problems such as malabsorption
Other chronic diseases (such as cancer, kidney disease, diabetes, etc.).
Long-term use of corticosteroid drugs and compounds, ie, more than 10 days of corticosteroid use per year.
Use of any anticoagulant drugs such as heparin, aspirin, clopidogrel, dipyridamole, warfarin and ticlopidine.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Interleukin-6. Timepoint: beginning and end of supplementation. Method of measurement: ELISA.;Spirometry. Timepoint: beginning and end of supplementation. Method of measurement: Spirometere.;Anthropometric measurements. Timepoint: beginning and end of supplementation. Method of measurement: Bioelectric impedance device.;Blood pressure. Timepoint: beginning and end of supplementation. Method of measurement: sphygmomanometer.;Dietary intake. Timepoint: beginning and end of supplementation. Method of measurement: Food record form.;Physical activity. Timepoint: beginning and end of supplementation. Method of measurement: international physical activity questionnaire.